|Bid||2.60 x 400|
|Ask||3.80 x 300|
|Day's range||2.59 - 2.69|
|52-week range||0.19 - 6.06|
|PE ratio (TTM)||N/A|
|Earnings date||18 May 2017 - 19 May 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.00|
Company Advances ThermoDox® for Treatment of Primary Liver Cancer Following Independent Data Monitoring Committee’s Unanimous Recommendation to Continue Phase III OPTIMA Study OPTIMA Study Enrollment Reached 74% Enrollment at Year-End, With Enrollment Completion Expected in Third Quarter 2018 Initiation of Enrollment of Phase I Portion of OVATION II Study of GEN-1 for Treatment of Ovarian Cancer Anticipated in the First Half of 2018 Cash Position of $25.5 Million at Year-End 2017 Provides Runway to Advance Development Priorities into Third Quarter of 2019
Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.
Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
Celsion Corp. shares rose nearly 20% in premarket trade Thursday after the company said the Food and Drug Administration had cleared its ovarian cancer therapy for a phase 1/2 clinical trial. The company ...
LAWRENCEVILLE, N.J., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the U.S. Food and Drug Administration (FDA), following the customary 30 day review period, has accepted its submission without comment, providing clearance for the OVATION II Study, the Company’s planned Phase I/II clinical trial of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer. The Phase I/II trial was developed with extensive input from the Company’s Medical Advisory Board. The OVATION II Study builds on the highly promising clinical and translational research data from the Phase IB dose-escalating OVATION Study where enrolled patients received escalating weekly doses of GEN-1, from levels beginning at 36mg/m², to 47mg/m², 61mg/m² and 79mg/m² weekly for 8 treatments in total, in combination with neoadjuvant chemotherapy, followed by interval debulking surgery.
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.